Pharmacokinetics and safety of roflumilast after once-daily repeated oral administration of 250 μg to patients with liver cirrhosis Child-Pugh A and B in comparison to healthy subjects

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A phase 1, single-center, open-label, non-randomized, one-period, repeated dose, parallel-group study design stratified according to hepatic function, in patients with liver cirrhosis Child-Pugh A and B in comparison to healthy subjects.